# Prostate Urothelial Cancer Program

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA AT DAVIS · 2020 · $43,903

## Abstract

PROJECT SUMMARY/ABSTRACT 
The central theme of the Prostate Urothelial Cancer Program is to improve the treatment outcomes of 
prostate and urothelial cancers through translational research. While targeted therapies and resistance 
mechanisms as well as localized outcomes vary between these two cancers, we established this program 
based on the overlapping expertise and research personnel with the common interest in these two 
genitourinary malignancies. The long-term goal of the program is to reduce mortality for advanced prostate 
and urothelial cancers and improve outcomes for localized prostate and urothelial disease. After intensive 
investigation of the unmet medical needs in managing these two malignancies, we direct our research interests 
at three highly interactive research themes: First, to investigate mechanisms of drug resistance to current 
therapies; Second, to identify molecular targets and develop therapeutic approaches; and third, to improve 
outcomes for localized cancers. These three themes will be addressed through a translational approach of 
preclinical models and clinical applications across disciplines that lead to mechanism-based transformative 
treatments for prostate and urothelial cancers to overcome resistance, optimize response and minimize toxicity. 
Although they are different diseases, we are approaching the prostate and urothelial disease spaces in parallel, 
to have similar impact on reducing mortality for advanced prostate and urothelial cancer, while improving 
outcomes for localized prostate and urothelial disease. 
PROGRAM ASPECTS 
 Co-leaders: Christopher Evans, MD; Allen Gao, MD, PhD; Chong-xian Pan, MD, PhD 
 Members: 21 
 Total Grant Funding (ADC): $5.2 million 
 Total Peer-Reviewed Funding (ADC): $4.8 million 
 Total NCI funding (ADC): $1.8 million 
 VA merit (additional funding not included above): $1,129,993 (7 projects funded) 
Total No. Publications: 360 
 Inter-programmatic publications: 186 (52%) 
 Intra-programmatic publications: 103 (29%) 
 Multi-institutional publications: 151 (42%) 
The Prostate Urothelial Cancer Program consists of 21 members from nine different departments and three 
different schools, with varied expertise in biochemistry, tumor biology, bioinformatics, urologic oncology, and 
medical oncology. The total peer-reviewed, cancer related funding (annual direct costs) has increased to 
$5.2 million (from $3.1 million in the previous period), with NCI funding increasing from $1.1 million in the 
previous period to $1.8 million in the current period.

## Key facts

- **NIH application ID:** 9993307
- **Project number:** 5P30CA093373-18
- **Recipient organization:** UNIVERSITY OF CALIFORNIA AT DAVIS
- **Principal Investigator:** Laura Marcu
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $43,903
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9993307

## Citation

> US National Institutes of Health, RePORTER application 9993307, Prostate Urothelial Cancer Program (5P30CA093373-18). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/9993307. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*